Merck Gains FDA Approval for Keytruda Plus Trodelvy in PD-L1 Positive Breast Cancer

MT Newswires Live06-25 19:25

Merck (MRK) said Thursday that the US Food and Drug Administration approved Keytruda and Keytruda Qlex in combination with Trodelvy for the first-line treatment of adults with PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer.

The approvals mark the first PD-1 inhibitor plus Trop-2-directed antibody-drug conjugate regimen in advanced triple-negative breast cancer, the company said.

Merck said phase 3 data showed the combination reduced the risk of disease progression or death by 35% versus Keytruda plus chemotherapy, with median progression-free survival improving to 11.2 months from 7.8 months.

Merck shares were 0.8% lower in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment